Niagen Bioscience (NAGE) Net Margin (2010 - 2026)

Niagen Bioscience (NAGE) has 16 years of Net Margin data on file, last reported at 20.07% in Q1 2026.

• On a quarterly basis, Net Margin rose 346.0% year-over-year to 20.07% in Q1 2026; TTM through Mar 2026 was 14.29%, a 122.0% increase from a year earlier, with the FY2025 full-year figure at 13.43%, up 485.0% from the prior year.
• Net Margin for Q1 2026 stood at 20.07%, up from 12.21% in the prior quarter.
• Over the last five years, Net Margin for NAGE reached as high as 24.65% in Q4 2024 and fell as low as 69.67% in Q2 2022.
• Historically, Net Margin has averaged 9.45% across 5 years, with a median of 1.27% in 2023.
• Across the five-year window, Net Margin tumbled 1495 bps in 2022 and jumped 3624 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 7.52% in 2022, then jumped by 83 bps to 1.27% in 2023, then soared by 2035 bps to 24.65% in 2024, then tumbled by 50 bps to 12.21% in 2025, then soared by 64 bps to 20.07% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 20.07% in Q1 2026, 12.21% in Q4 2025, and 13.47% in Q3 2025.